Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer
Crown, John P × Diéras, Véronique Staroslawska, Elzbieta Yardley, Denise A Bachelot, Thomas Davidson, Neville Wildiers, Hans Fasching, Peter A Capitain, Olivier Ramos, Manuel Greil, Richard Cognetti, Francesco Fountzilas, George Blasinska-Morawiec, Maria Liedtke, Cornelia Kreienberg, Rolf Miller, Wilson H Tassell, Vanessa Huang, Xin Paolini, Jolanda Kern, Kenneth A Romieu, Gilles #
Grune & Stratton
Journal of Clinical Oncology vol:31 issue:23 pages:2870-8
Metastatic breast cancer (MBC) remains an incurable illness in the majority of cases, despite major therapeutic advances. This may be related to the ability of breast tumors to induce neoangiogenesis, even in the face of cytotoxic chemotherapy. Sunitinib, an inhibitor of key molecules involved in neoangiogenesis, has an established role in the treatment of metastatic renal cell and other cancers and demonstrated activity in a phase II trial in MBC. We performed a randomized phase III trial comparing sunitinib plus capecitabine (2,000 mg/m2) with single-agent capecitabine (2,500 mg/m2) in patients with heavily pretreated MBC.